RE
CLLS

RBC Europe’s Cellectis CLLS Stock Holding History

RBC Europe’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-129
Closed -$3.76K – 1136
2017
Q4 		$3.76K Hold
129
– – ﹤0.01% 1004
2017
Q3 		$3.67K Buy
+129
New +$3.34K ﹤0.01% 1000

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RBC Europe's CLLS Position: Q1 2018 in Review

RBC Europe sold out of Cellectis (CLLS) in Q1 2018, closing a stake of 129 shares — an estimated $3.76K sold.

RBC Europe first reported a position in CLLS in Q3 2017 and held it in 2 quarters. The position peaked at $3.76K in Q4 2017. 69 funds tracked by Wall St. Rank hold CLLS as of Q1 2018.

  • RBC Europe reported no remaining Cellectis position as of Q1 2018 after selling out during the quarter.
  • RBC Europe sold 129 Cellectis shares in Q1 2018, an estimated $3.76K.
  • RBC Europe first reported a position in Cellectis in Q3 2017 and held it in 2 quarters.
  • RBC Europe's Cellectis position peaked at $3.76K in Q4 2017.
  • 69 funds tracked by Wall St. Rank held Cellectis as of Q1 2018.

Based on RBC Europe's 13F filing for Q1 2018, filed 9 Nov 2023.